Davita (NYSE:DVA) Releases Earnings Results, Beats Estimates By $0.12 EPS

Davita (NYSE:DVA) announced its earnings results on Thursday. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.12, Bloomberg Earnings reports. The business had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.86 billion. Davita had a net margin of 1.21% and a return on equity of 14.89%. The company’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period last year, the firm posted $1.05 earnings per share.

NYSE:DVA traded up $0.76 during midday trading on Friday, reaching $60.10. The stock had a trading volume of 5,379,970 shares, compared to its average volume of 2,841,014. The business’s fifty day simple moving average is $55.99. Davita has a 12-month low of $43.40 and a 12-month high of $79.11. The company has a current ratio of 1.12, a quick ratio of 1.11 and a debt-to-equity ratio of 2.06. The stock has a market cap of $9.87 billion, a PE ratio of 16.83, a P/E/G ratio of 0.62 and a beta of 1.59.

A number of brokerages have recently issued reports on DVA. TheStreet upgraded shares of Davita from a “c+” rating to a “b-” rating in a research report on Wednesday, July 24th. William Blair restated a “buy” rating on shares of Davita in a research report on Thursday, June 20th. Zacks Investment Research upgraded shares of Davita from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. ValuEngine upgraded shares of Davita from a “sell” rating to a “hold” rating in a research report on Monday, July 22nd. Finally, Robert W. Baird lowered shares of Davita from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $70.00 to $65.00 in a research report on Friday, July 26th. Eight investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $67.06.

Large investors have recently bought and sold shares of the stock. Barings LLC purchased a new position in Davita in the 1st quarter valued at $1,568,000. GHP Investment Advisors Inc. grew its position in Davita by 1.5% in the 1st quarter. GHP Investment Advisors Inc. now owns 30,265 shares of the company’s stock valued at $1,643,000 after buying an additional 460 shares during the last quarter. Clearbridge Investments LLC grew its position in Davita by 63.5% in the 1st quarter. Clearbridge Investments LLC now owns 798 shares of the company’s stock valued at $43,000 after buying an additional 310 shares during the last quarter. Northstar Group Inc. grew its position in Davita by 33.2% in the 2nd quarter. Northstar Group Inc. now owns 9,082 shares of the company’s stock valued at $511,000 after buying an additional 2,266 shares during the last quarter. Finally, CenturyLink Investment Management Co grew its position in Davita by 20.2% in the 1st quarter. CenturyLink Investment Management Co now owns 21,856 shares of the company’s stock valued at $1,187,000 after buying an additional 3,669 shares during the last quarter. Hedge funds and other institutional investors own 87.65% of the company’s stock.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Recommended Story: Economic Bubble

Earnings History for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.